JPWO2020043683A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020043683A5 JPWO2020043683A5 JP2021510824A JP2021510824A JPWO2020043683A5 JP WO2020043683 A5 JPWO2020043683 A5 JP WO2020043683A5 JP 2021510824 A JP2021510824 A JP 2021510824A JP 2021510824 A JP2021510824 A JP 2021510824A JP WO2020043683 A5 JPWO2020043683 A5 JP WO2020043683A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- her2 bispecific
- her2
- system inhibitor
- set forth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 63
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 63
- 239000003112 inhibitor Substances 0.000 claims description 49
- 206010028980 Neoplasm Diseases 0.000 claims description 36
- 239000003795 chemical substances by application Substances 0.000 claims description 25
- 102000019298 Lipocalin Human genes 0.000 claims description 15
- 108050006654 Lipocalin Proteins 0.000 claims description 15
- 201000011510 cancer Diseases 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 5
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 5
- 229960003852 atezolizumab Drugs 0.000 claims description 2
- 229950002916 avelumab Drugs 0.000 claims description 2
- 229940121420 cemiplimab Drugs 0.000 claims description 2
- 229950009791 durvalumab Drugs 0.000 claims description 2
- 230000001394 metastastic effect Effects 0.000 claims description 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 2
- 229960003301 nivolumab Drugs 0.000 claims description 2
- 229960002621 pembrolizumab Drugs 0.000 claims description 2
- 229950007123 tislelizumab Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 16
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 239000008177 pharmaceutical agent Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 1
- 238000002483 medication Methods 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 27
- 230000000259 anti-tumor effect Effects 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000037455 tumor specific immune response Effects 0.000 description 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18191041 | 2018-08-27 | ||
| EP18191041.5 | 2018-08-27 | ||
| PCT/EP2019/072754 WO2020043683A1 (en) | 2018-08-27 | 2019-08-27 | Combination therapies comprising cd137/her2 bispecific agents and pd-1 axis inhibitors and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021535149A JP2021535149A (ja) | 2021-12-16 |
| JPWO2020043683A5 true JPWO2020043683A5 (ko) | 2022-08-12 |
| JP7459058B2 JP7459058B2 (ja) | 2024-04-01 |
Family
ID=63578931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510824A Active JP7459058B2 (ja) | 2018-08-27 | 2019-08-27 | Ｃｄ１３７／ｈｅｒ２二重特異性物質とｐｄ－１系阻害物質とを含む併用療法およびその使用法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20210246219A1 (ko) |
| EP (1) | EP3843849A1 (ko) |
| JP (1) | JP7459058B2 (ko) |
| KR (1) | KR20210052468A (ko) |
| CN (1) | CN112955221A (ko) |
| AU (1) | AU2019328632A1 (ko) |
| CA (1) | CA3106881A1 (ko) |
| WO (1) | WO2020043683A1 (ko) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3946417A1 (en) * | 2019-03-29 | 2022-02-09 | Pieris Pharmaceuticals GmbH | Inhaled administration of lipocalin muteins |
| KR20220145859A (ko) * | 2020-02-28 | 2022-10-31 | 상하이 헨리우스 바이오테크, 인크. | 항cd137 작제물, 다중 특이적 항체 및 그 용도 |
| EP4213946A1 (en) * | 2020-09-18 | 2023-07-26 | Pieris Pharmaceuticals GmbH | Biomarker methods and uses |
| WO2022158889A1 (en) * | 2021-01-25 | 2022-07-28 | Yuhan Corporation | Methods for purifying an anti-4-1bb/anti-her2 bispecific antibody |
| EP4313099A2 (en) | 2021-03-23 | 2024-02-07 | Pieris Pharmaceuticals GmbH | Her2/4-1bb bispecific fusion proteins for the treatment of cancer |
| CN118632872A (zh) * | 2022-01-25 | 2024-09-10 | 美勒斯公司 | 用于治疗癌症的组合疗法 |
| CN116120461B (zh) * | 2022-04-29 | 2023-09-29 | 德琪(杭州)生物有限公司 | 新型抗药抗体以及其用途 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| EP0617706B1 (en) | 1991-11-25 | 2001-10-17 | Enzon, Inc. | Multivalent antigen-binding proteins |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| WO2002086083A2 (en) | 2001-04-20 | 2002-10-31 | Mayo Foundation For Medical Education And Research | Methods of enhancing cell responsiveness |
| EP1456652A4 (en) | 2001-11-13 | 2005-11-02 | Dana Farber Cancer Inst Inc | IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| DE10161767T1 (de) | 2002-07-03 | 2018-06-07 | Honjo Tasuku | Immunopotenzierende Zusammensetzungen, die einen Anti-PD-L1 Antikörper enthalten |
| ATE514713T1 (de) | 2002-12-23 | 2011-07-15 | Wyeth Llc | Antikörper gegen pd-1 und ihre verwendung |
| NZ563193A (en) | 2005-05-09 | 2010-05-28 | Ono Pharmaceutical Co | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| PT2397156T (pt) | 2005-06-08 | 2016-12-23 | The President And Fellows Of Harvard College | Métodos e composições para tratamento de infeções persistentes e cancro através da inibição da via de morte celular programada 1 (pd-1) |
| DK1907424T3 (en) | 2005-07-01 | 2015-11-09 | Squibb & Sons Llc | HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1) |
| EP2170959B1 (en) | 2007-06-18 | 2013-10-02 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| SI2350129T1 (sl) | 2008-08-25 | 2015-11-30 | Amplimmune, Inc. | Sestavki PD-1 antagonistov in postopek njihove uporabe |
| CN108997498A (zh) | 2008-12-09 | 2018-12-14 | 霍夫曼-拉罗奇有限公司 | 抗-pd-l1抗体及它们用于增强t细胞功能的用途 |
| JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ | Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用 |
| DK3279215T3 (da) | 2009-11-24 | 2020-04-27 | Medimmune Ltd | Målrettede bindemidler mod b7-h1 |
| EP2545078A1 (en) | 2010-03-11 | 2013-01-16 | UCB Pharma, S.A. | Pd-1 antibody |
| CN103608040B (zh) | 2011-04-20 | 2017-03-01 | 米迪缪尼有限公司 | 结合b7‑h1和pd‑1的抗体和其他分子 |
| CA2840018C (en) | 2011-07-24 | 2019-07-16 | Curetech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
| SI2785375T1 (sl) | 2011-11-28 | 2020-11-30 | Merck Patent Gmbh | Protitelesa proti PD-L1 in uporabe le-teh |
| KR102291355B1 (ko) * | 2012-11-30 | 2021-08-19 | 에프. 호프만-라 로슈 아게 | Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법 |
| CA3175360C (en) | 2013-05-31 | 2024-05-28 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| CN112457403B (zh) | 2013-09-13 | 2022-11-29 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| EA201991715A1 (ru) | 2013-09-27 | 2020-03-31 | Дженентек, Инк. | Композиции, содержащие антитело к pdl1 |
| US10202454B2 (en) | 2013-10-25 | 2019-02-12 | Dana-Farber Cancer Institute, Inc. | Anti-PD-L1 monoclonal antibodies and fragments thereof |
| KR20160089531A (ko) * | 2013-12-17 | 2016-07-27 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 항-her2 항체를 사용하여 her2-양성 암을 치료하는 방법 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| SG11201700207WA (en) | 2014-07-11 | 2017-02-27 | Genentech Inc | Anti-pd-l1 antibodies and diagnostic uses thereof |
| CR20170143A (es) | 2014-10-14 | 2017-06-19 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas |
| DK3237446T3 (en) | 2014-12-22 | 2021-07-26 | Pd 1 Acquisition Group Llc | Anti-PD-1-antistoffer |
| GB201500319D0 (en) | 2015-01-09 | 2015-02-25 | Agency Science Tech & Res | Anti-PD-L1 antibodies |
| AU2016258977C1 (en) * | 2015-05-04 | 2022-07-14 | Pieris Pharmaceuticals Gmbh | Anti-cancer fusion polypeptide |
| CN107922503B (zh) | 2016-03-04 | 2018-08-28 | 四川科伦博泰生物医药股份有限公司 | 一种pdl-1抗体、其药物组合物及其用途 |
-
2019
- 2019-08-27 JP JP2021510824A patent/JP7459058B2/ja active Active
- 2019-08-27 KR KR1020217007565A patent/KR20210052468A/ko unknown
- 2019-08-27 CN CN201980071320.7A patent/CN112955221A/zh active Pending
- 2019-08-27 EP EP19756382.8A patent/EP3843849A1/en active Pending
- 2019-08-27 WO PCT/EP2019/072754 patent/WO2020043683A1/en unknown
- 2019-08-27 AU AU2019328632A patent/AU2019328632A1/en active Pending
- 2019-08-27 US US17/271,149 patent/US20210246219A1/en active Pending
- 2019-08-27 CA CA3106881A patent/CA3106881A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Choi et al. | T-cell agonists in cancer immunotherapy | |
| van de Donk et al. | T-cell-engaging bispecific antibodies in cancer | |
| Antonia et al. | Immuno-oncology combinations: a review of clinical experience and future prospects | |
| TWI751101B (zh) | 對抗pd-1及pd-l1之拮抗劑與輻射療法組合之治療方法 | |
| CN108136025B (zh) | 一种使用免疫调节治疗癌症的新颖方法 | |
| JP2021155431A5 (ko) | ||
| JP2022050618A5 (ko) | ||
| HRP20220014T1 (hr) | Postupci liječenja raka kože davanjem inhibitora pd-1 | |
| JP2018518454A5 (ko) | ||
| JP2011507932A5 (ko) | ||
| JP2008530142A5 (ko) | ||
| Hovhannisyan et al. | CAR T cell-based immunotherapy and radiation therapy: potential, promises and risks | |
| JP2020527332A5 (ko) | ||
| KR102115203B1 (ko) | 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법 | |
| WO2022182483A1 (en) | Methods for local and systemic treatment of cancers, tumors and tumor cells | |
| CN114423453A (zh) | 使用偶联的抗cd25酞菁和抗pd1的基于光化学的癌症疗法近红外(nir)光免疫疗法(pit) | |
| JPWO2020043683A5 (ko) | ||
| JP7158677B2 (ja) | 溶血性レンサ球菌の菌体を含む製剤との併用療法 | |
| WO2019177011A1 (ja) | 腫瘍免疫賦活剤 | |
| JP7280387B2 (ja) | 抗原結合タンパク質 | |
| TW202304512A (zh) | 雙特異性t細胞銜接體之給藥 | |
| Clarke et al. | Fast Facts: Immuno-Oncology | |
| Forero-Torres et al. | Polatuzumab vedotin combined with obinutuzumab, cyclophosphamide, doxorubicin, and prednisone (G-CHP) for patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Preliminary results of a phase Ib/II dose-escalation study | |
| Kaur et al. | Therapeutic monoclonal antibodies in clinical practice against cancer | |
| JPWO2019143607A5 (ko) |